SCHEMBL5758218

SCHEMBL5758218

Fc1ccc(-c2cn(Cc3ccc(Cl)c(C(F)(F)F)c3)cn2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5B Q9UGL1 3/20 0.48
KDM4A O75164 1/20 0.45
KDM5A P29375 1/20 0.45
KDM4C Q9H3R0 1/20 0.45
NPC1 O15118 2/20 0.43
LMNA P02545 2/20 0.43
RAB9A P51151 2/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
OPRL1 P41146 1/20 0.43
PHF8 Q9UPP1 1/20 0.41
KCNN4 O15554 2/20 0.41
IDO1 P14902 1/20 0.41
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5756087 0.82 KDM4C (0.47) KDM4CPHF8KCNN4CYP3A4CYP2C9
SCHEMBL5758287 0.80 GRIN2B (0.41) KDM5BKDM5AKDM4CPHF8KCNN4
SCHEMBL5757747 0.80 PHF8 (0.51) KDM5BKDM4CNPC1LMNARAB9A
SCHEMBL5756587 0.76 NPC1 (0.48) KDM5BKDM4CNPC1LMNARAB9A
SCHEMBL5758470 0.76 NPC1 (0.53) KDM5BKDM4CNPC1LMNARAB9A
SCHEMBL5758123 0.75 KDM5B (0.50) KDM5BKDM4AKDM5AKDM4CNPC1
SCHEMBL5754960 0.74 P2RX7 (0.42) KDM5BKDM5AKDM4CNPC1LMNA
SCHEMBL5759382 0.72 HPGDS (0.59) KDM5BKDM4AKDM5AKDM4CNPC1
SCHEMBL5755514 0.71 NPC1 (0.60) KDM5BKDM5AKDM4CNPC1LMNA
SCHEMBL5756130 0.71 NPC1 (0.43) KDM5BKDM4AKDM5AKDM4CNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1194144-B1 ANTIBACTERIAL COMPOUNDS AFFINIUM PHARM INC (CA) 2006-11-02 EP claimed
US-20030149089-A1 Antibacterial compounds SMITHKLINE BEECHAM CORPORATION 2003-08-07 US claimed
JP-2003500357-A 2003-01-07 JP claimed
EP-1194144-A4 ANTIBACTERIAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2002-08-07 EP claimed
EP-1194144-A1 ANTIBACTERIAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2002-04-10 EP claimed
WO-2000071120-A1 ANTIBACTERIAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2000-11-30 WO claimed
EP-1194144-B1 ANTIBACTERIAL COMPOUNDS AFFINIUM PHARM INC (CA) 2006-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149089-A1 Antibacterial compounds MRPL21, MRPS28, SPOUT1 KDM5B 4450/4885KDM4A 4576/4885KDM5A 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.